ANI Pharmaceuticals, Inc.
ANIPHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. With a market capitalization of $1.80B, it sits in small-cap territory. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Market Cap
$1.80B
Beta
0.43
P/E (TTM)
20.95
P/E (Fwd)
7.36
EPS (TTM)
$3.78
EPS (Fwd)
$10.76
ROE
18.3%
ROA
5.0%
Cash
$326.1M
Total Debt
$630.2M
Free CF
$140.3M
52W Change
19.5%
Annual Financials
Cash vs Debt
On the balance sheet, ANIP has $326.1M in cash with $630.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $140.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 18.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 5.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $316.4M (2022) to $883.4M (2025), reflecting a 179% increase over the period.
The relatively low beta of 0.43 suggests ANIP is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing ANIP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.